Alimera Sciences, pSivida sales and marketing update

Alimera launched Iluvien fluocinolone acetonide intravitreal implant in the U.K. to treat diabetic macular edema (DME) for patients with private insurance. In January, NICE issued final guidance recommending against the use of Iluvien. Alimera said the guidance did not take into account its patient access scheme for Iluvien. The company said NICE will meet on May 15 to discuss the patient access scheme. Alimera could not be reached for details (see BioCentury, Jan. 28). ...